BNC Korea Co., Ltd. (KOSDAQ:256840)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,130.00
-40.00 (-0.77%)
Sep 16, 2025, 3:30 PM KST
-0.77%
Market Cap350.87B
Revenue (ttm)99.34B
Net Income (ttm)15.77B
Shares Out68.39M
EPS (ttm)233.23
PE Ratio22.02
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume459,930
Average Volume528,306
Open5,190.00
Previous Close5,170.00
Day's Range5,110.00 - 5,250.00
52-Week Range3,475.00 - 6,440.00
Beta0.80
RSI55.25
Earnings DateNov 14, 2025

About BNC Korea

BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj., temporary reduce glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity; Juvegel, temporary reduce nasolabial folds in adults; Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia; HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, CUTEGEL-M,... [Read more]

Sector Healthcare
Founded 2007
Employees 251
Stock Exchange KOSDAQ
Ticker Symbol 256840
Full Company Profile

Financial Performance

In 2024, BNC Korea's revenue was 89.23 billion, an increase of 10.16% compared to the previous year's 81.00 billion. Earnings were 13.31 billion, a decrease of -48.19%.

Financial Statements

News

There is no news available yet.